Eli Lilly and Company (LLY)
Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Will The Supply Shortage Weigh On Eli Lilly's Q2?
Eli Lilly stock (NYSE: LLY) will report its Q2 results on Thursday, August 8. The pharmaceutical giant is expected to garner $10 billion in sales and $2.70 in adjusted earnings per share, per the consensus estimates.
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
Eli Lilly is a leader in diabetes and obesity care through its medications Mounjaro and Zepbound. Now, it's also set to enter the $31 billion Alzheimer's market following FDA approval of donanemab.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These value-oriented businesses are also faithful dividend payers. Eli Lilly has scored multiple wins in recent months, and this established pharmaceutical giant is looking increasingly attractive for a long-term investment.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Lilly, Novo Nordisk battle for weight-loss market lands at the pharmacy shelf
As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?
Should You Buy Eli Lilly Before Aug. 8?
Eli Lilly shares have soared more than 230% over the past three years. The company has generated major growth thanks to its weight loss drugs.
Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic
My initial bearish thesis about Eli Lilly stock did not age well, as the stock has performed well since February despite being substantially overvalued. However, the market appears to be comfortable with the overvaluation as long as the company continues to capitalize on strong demand momentum for its diabetes and obesity drugs. Apart from the strong momentum of its stellar products like Mounjaro and Zepbound, there are several additional developments that contribute to my optimism.
Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?
A clinical trial starring patients with both obesity and heart failure says treatment with tirzepatide provides a big risk reduction. Tirzepatide is the active ingredient in both Mounjaro, a diabetes treatment, and Zepbound, a weight-management drug.
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
A recent study compared the effectiveness of tirzepatide against semaglutide. Tirzepatide has been more effective in helping people lose weight in trials, and the study corroborated that.
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says
All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration's drug shortage database. The update comes one day after Eli Lilly CEO David Ricks said shortages of Mounjaro and Zepbound would end "very soon.
